Beckley Psytech aims to have a positive impact on all stakeholders within the mental health treatment ecosystem. Alongside developing the next generation of treatments for people in need, we foster collaboration and shared purpose with our stakeholders to push forward research and support clinical trial participants and patients.
Working with patients in mind
In all of our work, we strive to make a profound impact on patient outcomes and seek to offer hope and new possibilities where limited options currently exist. We are committed to developing highly effective, accessible and well-tolerated treatments for mental health conditions.
Our early research has shown that our compounds can deliver rapid, robust and lasting treatment effects from a single administration and with a short time in the clinic. Learn more about our clinical trials below.
Patient Partnerships
Patient Council
In 2023, we established a Patient Council program with The Psychedelic Participant Advocacy Network (PsyPAN). The Council comprised 4 patient experts with personal experience of participating in psychedelic clinical trials, and 3 members of Beckley Psytech’s team with expertise in patient support and developing psychedelic clinical trials.
Three Patient Council workshops were convened over the course of a year to gather insights into the participants’ clinical trial experience across four key areas: clinical trial recruitment, pre-treatment, drug dosing, and post-treatment and integration. The workshops identified several areas for potential improvement and possible options were then co-developed by the patient experts and members of the Beckley Psytech team for consideration by psychedelic drug developers and clinical trial organisers in the form of a Patient Impact Report.
In recognition of the Patient Council project, and the collaboration between Beckley Psytech and PsyPAN, Beckley Psytech received the Silver Standard in OVID Health's 2024 Patient Partnership Index (PPI) in 2023 and 2024.
“Not only will the Patient Council help form best practices, the aim is that these insights and this knowledge will be shared for the benefit of the whole psychedelic-assisted therapy ecosystem. This is exactly the kind of connected thinking we need to ensure participant safety and wellbeing and to maximise the potential of these treatments.”
Ian Roullier
PsyPAN co-founder
Post-Participant Peer Support Pilot
We have provided PsyPAN with funding for an industry-wide post-participant peer support pilot program. The 12-month pilot is currently available to 20 UK-based participants who have taken part in a psychedelic-based clinical trial for a serious mental health illness.
If you have taken part in a psychedelic-based UK clinical trial and would like to take part, please email PsyPAN on peersupport@psypanglobal.org to register your interest.
Research Partnerships
Imperial College Research Grant
There is still much to learn about the effects of 5-MeO-DMT on the brain. To address this, Beckley Psytech has funded a research grant for Imperial College London to investigate the neurophysiological impact of BPL-003, our novel synthetic intranasal formulation of 5-MeO-DMT benzoate. Led by PhD student Tommaso Barba and overseen by Dr. Christopher Timmermann and Dr. David Erritzoe, this study aims to explore brain activity under the influence of BPL-003 using high-density electroencephalogram (HD-EEG) scans.
“This study will be the first to assess the effects of 5-MeO-DMT in the human brain and may provide significant advancements in our understanding of consciousness. 5-MeO-DMT is a psychedelic which appears to be particularly effective at inducing states of ego-dissolution and may help us to better understand the relationship between experience, the sense of self, and the brain.”
Dr. Christopher Timmermann
Head of the DMT Research Group (part of the Centre for Psychedelic Research at Imperial College London)
Beckley Foundation PhD Scholarship
Beckley Psytech is proud to fund an annual PhD scholarship to support the Beckley Foundation's commitment to undertaking rigorous research into psychedelic compounds. Most recently the funding has enabled the Beckley Foundation to undertake an international observational study in collaboration with Quantified Citizen, on the phenomenology and neurophysiology of meditation practice and psychedelic states.
Interested in partnering with Beckley Psytech? If our impact priorities align with yours, please contact us.
Chief Impact Advisor
caroline@beckleypsytech.com
Links to other websites do not imply affiliation or endorsement. Beckley Psytech does not control and is not responsible for their content.
